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ABSTRACT
Objective: In a large series of patients with cervical artery dissection (CeAD), a major cause of
ischemic stroke in young and middle-aged adults, we aimed to examine frequencies and corre-
lates of family history of CeAD and of inherited connective tissue disorders.
Methods: We combined data from 2 large international multicenter cohorts of consecutive pa-
tients with CeAD in 23 neurologic departments participating in the CADISP-plus consortium, fol-
lowing a standardized protocol. Frequency of reported family history of CeAD and of inherited
connective tissue disorders was assessed. Putative risk factors, baseline features, and
3-month outcome were compared between groups.
Results: Among 1,934 consecutive patients with CeAD, 20 patients (1.0%, 95% confidence
interval: 0.6%–1.5%) from 17 families (0.9%, 0.5%–1.3%) had a family history of CeAD. Family
history of CeAD was significantly more frequent in patients with carotid location of the dissection
and elevated cholesterol levels. Two patients without a family history of CeAD had vascular
Ehlers-Danlos syndrome with a mutation in COL3A1. This diagnosis was suspected in 2 addi-
tional patients, but COL3A1 sequencing was negative. Two patients were diagnosed with classic
and hypermobile Ehlers-Danlos syndrome, one patient with Marfan syndrome, and one with oste-
ogenesis imperfecta, based on clinical criteria only.
Conclusions: In this largest series of patients with CeAD to date, family history of symptomatic
CeAD was rare and inherited connective tissue disorders seemed exceptional. This finding
supports the notion that CeAD is a multifactorial disease in the vast majority of cases.
Neurology® 2014;83:1–9
GLOSSARY
CADISP 5 Cervical Artery Dissection and Ischemic Stroke Patients; CeAD 5 cervical artery dissection; CI 5 confidence
interval; CTD 5 connective tissue disorder; EDS 5 Ehlers-Danlos syndrome; vEDS 5 vascular Ehlers-Danlos syndrome.
Cervical artery dissection (CeAD), a major cause of ischemic stroke in young adults, is consid-
ered a complex disease, with multiple genetic variants and environmental factors contributing to
its occurrence.1,2 No consistent genetic association has been found so far.1 Given the low
incidence of the disease in the general population, heritability estimates based on twin or family
studies are not available, and data on family history of CeAD are scarce. Only one hospital-based
study from the Mayo Clinic, published 18 years ago, systematically examined the frequency of
family history of CeAD in a cohort of 200 patients with CeAD, reporting a frequency of 2.5%.3
This could be an overestimation because of a referral bias, given the single tertiary center
recruitment in a highly specialized institution.
Moreover, some rare inherited connective tissue disorders (CTDs) are known to cause or to
be associated with CeAD, i.e., mostly vascular Ehlers-Danlos syndrome (vEDS), and perhaps, to
a lesser extent, other types of EDS, Marfan syndrome, or osteogenesis imperfecta, although the
evidence for these is much weaker.2,4 However, the prevalence of these monogenic diseases has
never been systematically assessed in large patient series. Evaluating the frequency of heritable
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forms of CeAD in a multicenter setting could
be important to guide screening and genetic
counseling strategies for patients with CeAD
and their families.
We aimed to examine the frequencies and
correlates of family history of CeAD and of
the aforementioned inherited CTD in 2 large
contemporary multicenter cohorts of patients
with CeAD (CADISP-plus consortium).
METHODS Study population. The multicenter CADISP-
plus consortium comprised 2,021 patients with CeAD from both
the CADISP clinical study (n 5 983)5 and the Paris-Lariboisière/
Zürich/Bern CeAD registry (n5 1,038).6,7 Structure andmethods of
each of these studies have been described in detail previously.5,7–9
Briefly, we included consecutive patients evaluated in a department
of neurology with a diagnosis of CeAD, following a standardized
protocol (table 1, figures e-1 and e-2, and e-Methods [on the
Neurology® Web site at Neurology.org] for inclusion criteria and
recruiting centers). To be included, patients with CeAD had to
present with a mural hematoma, aneurysmal dilation, long tapering
stenosis, intimal flap, double lumen, or occlusion .2 cm above the
carotid bifurcation revealing an aneurysmal dilation or a long tapering
stenosis after recanalization, in a cervical artery (internal carotid or
vertebral); iatrogenic dissections were excluded. Monogenic CTDs,
which were an exclusion criterion for genetic analyses, were included
in the CADISP clinical study. The Paris-Lariboisière/Zürich/Bern
CeAD registry included patients with first-ever CeAD only.
Between 2004 and 2009, the CADISP clinical study included all
consecutive patients evaluated in several departments of neurology
with a diagnosis of CeAD. Patients were recruited both prospectively
and retrospectively. Retrospective patients are participants who had a
qualifying event before the beginning of the study in each center and
were identified through local registries of patients with CeAD. The
vast majority of these had a qualifying event between 1999 and
2009 (,4% before 1999). In the Paris-Lariboisière/Zürich/Bern
Registry on CeAD, patients were included prospectively between
1985 and 2013 (e-Methods).
After excluding patients without reliable information on fam-
ily history, 1,934 patients with CeAD were available (CADISP
study: n 5 921; Paris-Lariboisière/Zürich/Bern registry: n 5
1,013), from 8 countries and 23 centers (figure e-1).
Variable definition. Family history of CeAD was defined by re-
ported history of CeAD in father, mother, siblings, children, or
any other defined relative of the index patient. Whenever possi-
ble, medical records were obtained for the affected relative to con-
firm the diagnosis and specify the age at occurrence of CeAD, the
dissection site, and presence or absence of cerebral or retinal ische-
mia (ischemic stroke or TIA, including transient monocular
blindness). We systematically searched for history of previously
diagnosed vEDS, classic or hypermobile EDS,10,11 Marfan syn-
drome,12 or other known inherited CTD according to established
criteria.4 When patients were aphasic or had cognitive deficits,
information on personal and family history was collected from a
close relative. Each patient’s personal medical records were exam-
ined in detail. When an inherited CTD was suspected based on
suggestive clinical features or family history, the patient was sent
to a specialized genetics center for further diagnostic workup.
Presence of cerebral or retinal ischemia, of arterial occlusion,
stenosis, aneurysmal dilation (e-Methods), or multiple dissections
at admission, and 3-month CeAD recurrence rates were recorded.
Putative risk factors (hypertension, hypercholesterolemia,
migraine, infection, and trauma preceding the dissection) are
defined in e-Methods.
Statistical analyses. To compare clinical and radiologic charac-
teristics as well as risk factor distribution between CeAD patients
with and without a family history of CeAD, we first performed
univariate analyses using Fisher exact test for categorical and
Wilcoxon-Mann-Whitney test for continuous variables.
Multivariable logistic regression models were then applied,
adjusting for age and sex, as well as for study (CADISP clinical
study, Paris-Lariboisière/Zürich/Bern CeAD registry) in a
secondary analysis. Sensitivity analyses were performed after
excluding one random patient from each of the 3 related
patient pairs with a family history of CeAD. In addition, we
verified the stability of associations after additionally adjusting
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Table 1 Participating centers
Country and city
No. (%) of
patients
(by country)
No. (%)
patients
(by center)
Argentina 8 (0.4)
Cordoba 8 (0.4)
Belgium 34 (1.8)
Brussels 15 (0.8)
Leuven 19 (1.0)
Switzerland 711 (36.8)
Basel 89 (4.6)
Zürich 269 (13.9)
Bern 353 (18.3)
Germany 151 (7.8)
Heidelberg 145 (7.5)
Ludwigshafen 6 (0.3)
France 693 (35.8)
Lille 114 (5.9)
Paris 496 (25.6)a
Amiens 28 (1.5)
Dijon 35 (1.8)
Besançon 20 (1.0)
Finland 174 (9.0)
Helsinki 174 (9.0)
Italy 161 (8.3)
Brescia 82 (4.2)
Milano 39 (2.0)b
Perugia 19 (1.0)
Monza 20 (1.0)
Roma 1 (0.1)
Turkey 2 (0.1)
Istanbul 2 (0.1)
aOf which 56 (2.9) for Hôpital Sainte-Anne, 49 (2.5) for
Hôpital Pitié-Salpêtrière, and 391 (20.2) for Hôpital
Lariboisière.
bOf which 13 (0.7) for Milano Ospedale Maggiore and 26
(1.3) for Milano Ospedale San Raffaele.
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for the retrospective vs prospective recruitment for CADISP
clinical study participants. Analyses were performed using
Statistical Analyses System software, version 9.2 (SAS Institute,
Cary, NC).
Standard protocol approvals, registrations, and patient
consents. The study protocols were approved by relevant local
authorities in all participating centers and conducted according
to national rules concerning ethics committee approval and
informed consents.5,7 The CADISP study is registered with
clinicaltrials.gov (NCT00657969); see also www.cadisp.com.
RESULTS Among 1,934 patients with CeAD, 20 pa-
tients (1.0%, 95% confidence interval [CI]: 0.6%–
1.5%) from 17 families (0.9%, 0.5%–1.3%) had a
family history of CeAD; of these, 13 patients had a
family history of CeAD in a first-degree relative
(0.7%, 0.3%–1.0%). Characteristics of these patients
are presented in table 2. In most cases, there were only 2
affected cases per family, including the index patient.
Two families had 3 affected members. In one of these,
only males were affected, including 2 brothers and
1 maternal cousin, suggesting a possible X-linked
inheritance pattern. For 3 families (6 patients), both
affected relatives were included in the CADISP-plus
study (table 2). Of the remaining 14 patients with a
positive family history, details on CeAD characteristics
of the affected relative could be obtained in 11 patients.
These characteristics remained undetermined for 3
patients (15%).
Patients with CeAD who had a family history of
CeAD more often had carotid (mostly left carotid)
than vertebral dissection and more frequently had ele-
vated total cholesterol levels ($6.20 mmol/L) at
admission compared to patients with CeAD without
such a family history (table 3). There was also a
Table 2 Characteristics of patients with a family history of CeAD
Family
Clinical features of index patient Clinical features of affected relative
Patient Country City
Age,
y Sex
Location of
dissection
Cerebral
ischemia
Relative(s) with
CeAD
Age,
y
Location of
dissection
Cerebral
ischemia
1 1 Switzerland Basel 60 F Left carotid 1 Brother 49 Left carotid 1
2 2 Germany Heidelberg 31 M Left vertebral 1 Father 31 Left carotid 1
3 3 Germany Heidelberg 43 M Left carotid 1 Sister (patient 4) 41 Left carotid 1
3 4 Germany Heidelberg 41 F Left carotid 1 Brother (patient 3) 43 Left carotid 1
4 5 France Lille 48 M Bilateral carotid 0 Male cousina 59 Left carotid 1
5 6 France Paris 53 M Left carotid 1 Brother 51 Left carotid 1
Male cousin 46 Right carotid 0
6 7 France Amiens 49 M Left carotid 1 Sister (patient 8) 45 Right carotid 1
6 8 France Amiens 45 F Right carotid 1 Brother (patient 7) 49 Left carotid 1
7 9 France Dijon 44 F Left vertebral 1 Female cousin 50 Carotid 1
8 10 France Paris 53 F Left carotid 0 Male cousin NA NA NA
Male cousin NA NA NA
9 11 Italy Milan 36 F Left carotid 1 Uncle 60 Carotid 1
10 12 France Paris 45 M Left carotid 1 Brother (patient
13)
50 Left carotid 1
10 13 France Paris 50 M Left carotid 1 Brother (patient
12)
45 Left carotid 1
11 14 France Paris 44 M Right carotid 1 Mother NA Carotid NA
12 15 Switzerland Bern 40 F Left carotid 0 Sister NA NA NA
13 16 Switzerland Bern 38 M Left carotid 0 Brother 48 Carotid 0
14 17 Switzerland Bern 53 F Left carotid 1 Sister NA Carotid 1
Brother NA Carotid 1
15 18 Switzerland Zürich 38 M Left carotid 0 Male cousinb 57 Common carotid 0
16 19 Switzerland Bern 48 F Left carotid 1 Sister NA Right carotid 1
17 20 Switzerland Bern 38 F Bilateral carotid 1 Uncle NA NA NA
Abbreviations: CeAD 5 cervical artery dissection; NA 5 not available.
Cerebral ischemia 5 ischemic stroke or TIA, including transient monocular blindness.
a This patient also had a dissection of the left subclavian artery, and the brachiocephalic artery extended to the right common carotid artery and the right
vertebral artery (without aortic dissection).
b This patient also had aortic dissection.
Neurology 83 November 25, 2014 3
ª 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
nonsignificant trend toward a higher prevalence of
migraine, especially migraine without aura (table 3).
Patients with a family history of CeAD did not differ
significantly from those without such a family history
regarding other putative risk factors, baseline charac-
teristics (especially frequency of multiple dissections),
and short-term (3 months) recurrence rate (table 3).
Results were substantially unchanged, although no
longer reaching statistical significance, when exclud-
ing one random patient from each of the 3 related
patient pairs with a family history of CeAD.
None of the patients with a family history of
CeAD had been diagnosed with a known inherited
CTD. Among patients with CeAD who had a family
history of CeAD, 2 patients (0.1%, 0.0%–0.2%) had
clinically and genetically confirmed vEDS, with mu-
tations detected in the COL3A1 gene. In both cases,
CeAD occurred before age 30 years, and the diagnosis
of vEDS was already known before the dissection,
with a history of colon rupture. Characteristics of
the dissection and other clinical features of vEDS in
these patients are described in table 4. There were 2
Table 3 Putative risk factors, and clinical and radiologic features of patients with and without a family history of CeAD
Family history of CeAD
p OR (95% CI)a pa pb pcYes (n 5 20) No (n 5 1,914)
Age, y 44.9 6 7.0 44.6 6 9.8 0.94 1.00 (0.96–1.05) 0.90 0.87 0.82
Women 10 (50.0) 814 (42.5) 0.50 1.35 (0.56–3.26) 0.50 0.51 0.71
Putative risk factorsd
Hypertensione 5 (25.0) 477 (25.0) 1.00 1.01 (0.35–2.87) 0.99 1.00 0.86
Hypercholesterolemiaf 5 (41.7) 222 (17.0) 0.041 3.51 (1.07–11.44) 0.038 0.027 0.059
Total cholesterol 5.5 6 1.0 5.1 6 1.2 0.17 1.29 (0.83–1.99) 0.26 0.21 0.42
Triglycerides 1.1 6 0.2 1.4 6 1.0 0.29 0.44 (0.12–1.55) 0.20 0.21 0.23
Body mass index, kg/m2 23.5 6 3.1 24.4 6 4.0 0.41 0.96 (0.84–1.11) 0.58 0.60 0.46
Current smoker 2 (10.0) 559 (29.3) 0.080 0.27 (0.06–1.17) 0.081 0.083 0.14
Infection in previous monthg 2 (10.0) 255 (15.0) 0.76 0.63 (0.15–2.74) 0.54 0.52 0.71
Cervical trauma in previous month 7 (36.8) 552 (29.0) 0.45 1.45 (0.56–3.72) 0.44 0.50 0.20
Migraine 10 (52.6) 626 (33.5) 0.090 2.20 (0.87–5.59) 0.096 0.11 0.18
Migraine with aura 3 (15.8) 228 (12.2) 0.72 1.31 (0.38–4.58) 0.67 0.70 0.45
Migraine without aura 8 (42.1) 445 (23.8) 0.099 2.31 (0.91–5.89) 0.080 0.085 0.22
Clinical and radiologic featuresh
Cerebral ischemia at admission 15 (75.0) 1,444 (76.0) 1.00 0.96 (0.34–2.66) 0.93 0.91 0.61
ICA dissectionh 18 (90.0) 1,231 (67.7) 0.031 4.52 (1.03–19.80) 0.045 0.043 0.083
Left ICA dissectionh 16 (80.0) 711 (39.3) 3.08 3 1024 6.39 (2.12–19.30) 0.0010 0.0010 0.0018
Right ICA dissectionh 4 (20.0) 604 (33.5) 0.24 0.49 (0.16–1.47) 0.20 0.21 0.17
Multiple dissections 2 (10.0) 291 (15.2) 0.76 0.59 (0.14–2.60) 0.49 0.49 0.68
Arterial occlusion 7 (36.8) 615 (34.3) 0.81 1.14 (0.44–2.91) 0.79 0.79 0.77
Stenosis 12 (63.2) 1,099 (61.8) 1.00 1.05 (0.41–2.69) 0.92 0.94 0.97
Aneurysmal dilation 3 (15.8) 184 (10.3) 0.44 1.62 (0.47–5.62) 0.45 0.49 0.82
CeAD recurrence at 3 mo 0 (0) 27 (1.6) 1.00 NA NA NA NA
Abbreviations: CeAD 5 cervical artery dissection; CI 5 confidence interval; ICA 5 internal carotid artery; NA 5 not available; OR 5 odds ratio.
Data are mean 6 SD or n (%).
a Age- and sex-adjusted.
bAdditionally adjusted for study (CADISP clinical study or Paris-Lariboisière/Zürich/Bern CeAD registry).
c Analysis restricted to 17 unrelated familial cases (i.e., for families 3, 6, and 10, only one patient was included in the analyses).
dMissing values are ,2.5%, except for hypercholesterolemia (n 5 12/1,304 for patients with and without family history of CeAD), total cholesterol
(n 5 12/1,304), triglycerides (n5 10/1,296), body mass index (n 5 16/1,225), infection (n 5 20/1,699), and 3-month follow-up (n 5 20/1,669).
e Associations with hypertension were still nonsignificant after removing 308 patients from the Paris-Lariboisière/Zürich/Bern CeAD registry who
were included before 2000 and in whom hypertension was defined as systolic blood pressure $160 mm Hg or diastolic blood pressure $95 mm Hg:
OR (95% CI) 5 0.87 (0.27–2.79), p 5 0.82.
fHypercholesterolemia was defined here as total cholesterol $2.4 g/L (6.21 mmol/L).
g Previous week for CADISP.
hNinety-four patients with dissections both in a vertebral and a carotid artery were excluded.
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additional patients in whom vEDS was suspected
after the CeAD, but COL3A1 DNA sequencing
was negative. A detailed description of these patients
is provided in table e-1. One patient had clinical diag-
nosis of Marfan syndrome, because he had a positive
family history and fulfilled the revised Ghent criteria,
despite the absence of genetic testing (table 4).12 Two
additional patients had features of Marfan syndrome,
but did not fulfill established clinical diagnostic crite-
ria (table e-1).12 One patient was diagnosed with
classic EDS, one with hypermobile EDS and one
with osteogenesis imperfecta, all without genetic con-
firmation, but fulfilling clinical diagnostic criteria
(table 4).10,11,13
DISCUSSION In the largest series of patients with
CeAD to date, comprising nearly 2,000 patients re-
cruited through departments of neurology (mean
age 45 years, 57% men), family history of CeAD
was very rare, and was associated with carotid location
and elevated cholesterol levels. A trend toward an
association of familial CeAD with migraine without
aura was also observed. Underlying inherited CTDs,
known to be associated with dissection, were excep-
tional, and all occurred in patients without family his-
tory of CeAD. Two patients had clinically and
genetically confirmed vEDS. One patient had Marfan
syndrome, one was diagnosed with classic EDS, one
with hypermobile EDS, and one with osteogenesis
imperfecta, based on clinical criteria.
In the only previous study to our knowledge that
systematically addressed the frequency of family his-
tory of CeAD in 200 patients with CeAD,3 10 pa-
tients from 8 families had a family history of
dissection. Of these, 5 patients (2.5%, 0.3%–4.7%)
from 3 families (1.5%, 0%–3.2%) had a family his-
tory of dissection in the cervical arteries (the remain-
ing being in intracranial arteries, aorta, or renal artery)
and in 4 patients, the family history of CeAD was in a
first-degree relative (2.0%, 0.1%–3.9%).3 The
slightly higher prevalence of familial CeAD compared
with our series could be explained by sampling fluc-
tuation (CIs overlap), or selection bias, because
recruitment through a single tertiary center could
have led to an overrepresentation of unusual, familial
cases,3 while our multicenter recruitment may be
more representative of the community. Although
rare, the observed frequency of family history of
CeAD is higher than expected by chance given the
low disease incidence. Indeed, based on an estimated
CeAD prevalence of 1/1,000,14,15 the probability for a
patient with CeAD with 1 sibling and 2 children of
having a first-degree relative who had a CeAD by
mere chance is ,0.5% (e-Methods).
Although power is limited by the small number
of familial cases, we describe some differences in
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characteristics of patients with and without a family
history of CeAD, with a higher frequency of carotid
dissection (90% vs 68%) and of hypercholesterolemia
(42% vs 17%) in the former. These findings suggest
that genetic determinants of CeADmay differ accord-
ing to the dissection site. The more marked familial
clustering for carotid dissection, which was suggested
previously in a study comparing patients with CeAD
who had a family history of CeAD with published
findings from patients with sporadic CeAD,16 could
point to a more important contribution of genetic
factors in this vessel location. Most patients with a
family history of CeAD had a dissection in the left
carotid artery, suggesting that inherited anatomical
factors might have a role. The higher frequency of
hypercholesterolemia in patients with CeAD who
had a positive family history is intriguing, because
we have previously shown that patients with CeAD
have a significantly lower prevalence of hypercholes-
terolemia than healthy controls or patients with an
ischemic stroke of another etiology matched on age
and sex.9 This may reflect that familial CeAD has
different underlying mechanisms from sporadic
CeAD, and may also point to shared pathways or
shared genetic variation between CeAD and lipid
metabolism, with allelic heterogeneity. Of note, for
patients in whom detailed information was available,
most relatives had a dissection in the same artery type
as the index patients (17/19); age at CeAD occur-
rence was often similar within families, as previously
described.15
Only 2 patients with CeAD (without family his-
tory of CeAD) had a genetically confirmed diagnosis
of vEDS, which was known before the CeAD. From a
clinical perspective, our findings suggest that clini-
cally obvious inherited CTDs are extremely rare in
patients with CeAD, because only 0.1% of our pa-
tients had a diagnosis of vEDS that was clinically evi-
dent and genetically confirmed. vEDS is a very rare
condition, with a prevalence estimated at 0.2–1/
100,000,17 and although CeAD is one of its classic
complications, it was described in only 2% of the
patients in the largest, partly retrospective series of
patients with genetically confirmed vEDS.18,19 The
first major complication of vEDS was shown to occur
before age 40 in 80% of 220 patients,19 and the
reported mean age at occurrence of the first cerebro-
vascular complication was 28 years.18 In agreement
with these reports, CeAD occurred before age 30 in
both patients with vEDS in our series. One of 1,934
patients was previously known to have Marfan syn-
drome, which is close to the prevalence of this disease
in the general population, estimated between 1/3,000
and 1/5,000.20 Three patients, who had their dissec-
tion between 2001 and 2006, had been diagnosed
beforehand with classic or hypermobile EDS and
with osteogenesis imperfecta (prevalence for these dis-
eases range between approximately 1/100,000 and
1/20,000), without molecular confirmation, but the
genetic investigation of these disorders was challeng-
ing before the advent of next-generation sequencing,
and not thought to be a requirement for diagnosis.
Clinical implications are less dramatic because these
diseases do not expose to an increased risk of life-
threatening complications, such as vascular or hollow
organ rupture, as is the case for vEDS.4 Overall,
inherited CTDs, including EDS, Marfan syndrome,
and osteogenesis imperfecta, appeared very rare in this
large multicenter series of patients with CeAD, and
CeAD was typically not the first symptom revealing
the inherited disorder.
Our study has limitations. Only short-term clini-
cal follow-up was available at this stage, so that we
could not verify the previously reported association
of CeAD family history with long-term CeAD recur-
rence.3 The number of patients with a family history
of CeAD being small, association estimates have wide
CIs and require confirmation in independent sam-
ples. Family members with a history of CeAD were
not all included in CADISP-plus, therefore preclud-
ing detailed clinical description, although minimal
information on CeAD characteristics could be ob-
tained in the majority of cases. The diagnosis of
CeAD could not formally be verified in 17% of the
affected relatives. An underestimation of familial
CeAD cannot be excluded, because (1) many CeADs
causing strokes among family members remained
undiagnosed in the last century because of lack of
knowledge and proper imaging equipment, (2) CeAD
with minor or no clinical symptoms, or leading to
very severe rapidly fatal stroke, is probably still under-
diagnosed, (3) some patients may have limited knowl-
edge of their relatives’ health. However, history of
symptomatic CeAD is clinically more relevant and,
while a systematic screening of CeAD in all first-
degree relatives of patients with CeAD with arterial
imaging might increase the diagnostic yield by poten-
tially capturing some cases of asymptomatic CeAD, it
would be unrealistic and ethically challenging to per-
form on such a large sample. Patients with CeAD
who had inherited CTDs were diagnosed only in
centers from Paris (1.0% of all Paris patients) and
Zürich (0.4% of all Zürich patients). Although these
were among the cities with the largest recruitment, it
could point to an underestimation of such disorders
in other centers. In France, many national referral
centers for rare vascular disorders are located in Paris,
which could lead to a recruitment and ascertainment
bias. However, the proportion of patients with CeAD
with inherited CTD remains small (#1.0%), even in
the cities with the largest number of diagnosed cases.
Because patients with severe inherited CTDs, such as
6 Neurology 83 November 25, 2014
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vEDS, often benefit from close multidisciplinary
follow-up in highly specialized referral centers, they
may also be hospitalized there when they have a
CeAD, and may therefore not have been included
in our study. However, given the low prevalence of
these disorders, this is unlikely to have led to a major
underestimation of their frequency among patients
with CeAD at population level. Finally, we cannot
formally exclude mild forms of inherited CTD with
incomplete penetrance or CeAD as the first isolated
symptom,15,21 because patients were not systemati-
cally screened for mutations in genes such as
COL3A1, FBN1, TGFBR1, or TGFRB2, responsible
for vEDS,19 Marfan syndrome,12 and Loeys-Dietz
syndrome.22 In earlier studies, systematic search for
mutations in COL3A1 among 53 patients with
CeAD,23–26 and in TGFBR1 and TGFBR2 among
56 consecutive patients with CeAD,21 identified
potentially deleterious mutations in COL3A1 among
2 cousins with CeAD,23 and in TGFBR2 in 2 unre-
lated patients with CeAD,21 but none of them
fulfilled the clinical diagnostic criteria of vEDS or
Loeys-Dietz syndrome, possibly pointing to muta-
tions with incomplete penetrance.10,11,22 Whether
identifying such mutations is clinically relevant, espe-
cially regarding risk of CeAD recurrence, other vas-
cular complications, and familial risk, is unclear to
date. Noteworthy, skin biopsies performed in series
of 7 to 65 patients with CeAD have shown that about
half of these patients have ultrastructural skin connec-
tive tissue abnormalities on electron microscopy, the
most common pattern being described as composite
fibrils within collagen bundles and elastic fiber abnor-
malities with minicalcifications and fragmenta-
tion.2,27–30 Moreover, skin biopsies performed in
healthy relatives of 3 index patients with CeAD (from
3 distinct families) have suggested that these ultra-
structural skin connective tissue changes may be
inherited according to an autosomal dominant pat-
tern, but linkage studies were inconclusive.31 Similar
pathologic changes in the wall of temporal arteries
were also described in discordant identical twin pairs,
both in the affected and unaffected twin.32 These
findings could suggest underlying connective tissue
fragility in patients with CeAD, which may in some
cases be inherited, perhaps as part of uncharacterized
inherited CTD with incomplete penetrance.
In 2 large multicenter cohorts of patients with
CeAD, both family history of symptomatic CeAD
and known inherited CTDs were very rare. In clinical
practice, given the psychological distress and anxiety
that is often generated by the occurrence of CeAD,33
which usually affects young individuals with few or
no vascular risk factors,9 this is important information
for patients and their families. Based on current
knowledge, we believe that systematic screening for
mutations in genes responsible for inherited CTDs is
not clinically justified in monosymptomatic cases.4
For research purposes, our findings justify ongoing
efforts to identify genetic susceptibility factors for
CeAD by genetic association studies,4 or next-
generation sequencing, rather than a family-based
linkage approach, except for the very rare families
with multiple cases.
AUTHOR AFFILIATIONS
From the Department of Neurology (S.D., D.H., H.C., C.S., M.-G.B.),
Lariboisière Hospital, DHU Neurovasc Paris Sorbonne, Paris; INSERM
Unit UMR-S 1161 (S.D., S.S., D.H., H.C., E.T.-L.), Paris; University
Paris 7–Denis-Diderot (S.D., S.S., D.H., H.C., C.S., E.T.-L., M.-G.B.),
DHU Neurovasc Sorbonne Paris Cité; Department of Neurology (S.D.,
D.L.), EA1046, Lille University Hospital; Department of Epidemiology
and Public Health (S.D., J.C.), INSERM U744, Pasteur Institute, Lille,
France; INSERM U897 (S.D.), Bordeaux University, Bordeaux, France;
Department of Neurology (B.G.S., H.S., S.J., U.F., M.A.), University
Hospital Inselspital, Bern, Switzerland; Department of Neurology (J.J.
M.), Sanatorio Allende, Cordoba, Argentina; Department of Neurology
(M.K., C.L., C.G.-G.), Heidelberg University Hospital, Germany;
Department of Neurology (H.S.), Zürich University Hospital, Switzer-
land; Electron Microscopy Laboratory (I.H.), Institute of Pathology Uni-
versity Hospital, Germany; Department of Neurology and Stroke Center
(S.E., P.A.L.), Basel University Hospital; Neurorehabilitation Unit (S.E.),
University and University Center for Medicine of Aging and Rehabilita-
tion Basel, Felix Platter Hospital, Basel, Switzerland; Department of
Neurology (T.M.M., A.J.M., T.T.), Helsinki University Central Hospi-
tal, Finland; Department of Clinical and Experimental Sciences (A.P.,
P.C.), Neurology Clinic, University of Brescia, Italy; KU Leuven–
University of Leuven (V.T.), Department of Neurosciences, VIB–Vesalius
Research Center, Experimental Neurology–Laboratory of Neurobiology,
Leuven; Vesalius Research Center (V.T.), VIB, Leuven, Belgium; Paris
Descartes University (E.T.), INSERM UMR S894, Department
of Neurology, Sainte-Anne Hospital, Paris; Department of Neurology
(E.T.), University Hospital of Caen, France; Department of Rehabilitation
(S.P.), Santa Lucia Hospital, Rome; Department of Neurology (M.S.),
San Raffaele University Hospital, Milano, Italy; Department of Neurology
(Y.S.), Pitié-Salpêtrière University Hospital, Paris; Department of Neurol-
ogy (Y.B.), Dijon University Hospital, France; Istanbul University (A.A.),
Cerrahpasa Medical School, Neurology Department, Turkey; Department
of Neurology (C. Lichy), Memmingen Hospital, Germany; Department of
Neurology (C. Lamy), Amiens University Hospital, France; Department of
Neurology (A.G.), Ludwigshafen Hospital, Germany; Stroke Unit (V.C.),
Perugia University Hospital, Italy; Department of Rehabilitation (T.B.),
Schmieder-Klinik, Heidelberg, Germany; Department of Molecular
Genetics (E.T.-L.), Lariboisière Hospital, Paris; Division of Medical
Genetics (D.P.G.), Referral Center for Fabry Disease and Inherited Dis-
orders of Connective Tissue, CHU Raymond Poincaré (AP-HP), Garches;
University of Versailles–St Quentin en Yvelines (D.P.G.), EA 2493, Mon-
tigny; National Referral Center for Rare Vascular Diseases (M.F.), Hôpital
Européen Georges-Pompidou HEGP, Paris, France; NeuroCenter (R.W.
B.), Clinic Hirslanden Zürich, Switzerland; and Cerebrovascular Disease
Unit (A.B.), IRCCS Foundation C. Besta Neurological Institute, Milan
Italy.
AUTHOR CONTRIBUTIONS
Dr. Stéphanie Debette: study concept and design, analysis and interpreta-
tion, statistical analysis, study supervision or coordination, drafting/revising
the manuscript, obtaining funding, acquisition of data. Dr. Barbara Goeggel
Simonetti: analysis and interpretation, drafting/revising the manuscript,
acquisition of data. Mrs. Sabrina Schilling: statistical analysis, analysis and
interpretation. Dr. Juan José Martin: acquisition of data, drafting/revising
the manuscript. Dr. Manja Kloss: acquisition of data, drafting/revising the
manuscript. Dr. Hakan Sarikaya: acquisition of data, drafting/
revising the manuscript. Dr. Ingrid Hausser: drafting/revising the manu-
script. Dr. Stefan Engelter: acquisition of data, drafting/revising the
Neurology 83 November 25, 2014 7
ª 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
manuscript. Dr. Tiina M. Metso: acquisition of data, drafting/revising
the manuscript. Dr. Alessandro Pezzini: acquisition of data, drafting/revising
the manuscript. Dr. Vincent Thijs: acquisition of data, drafting/revising the
manuscript. Dr. Emmanuel Touzé: acquisition of data, drafting/revising
the manuscript. Dr. Stefano Paolucci: acquisition of data, drafting/revising
the manuscript. Dr. Paolo Costa: acquisition of data. Dr. Maria Sessa:
acquisition of data, drafting/revising the manuscript. Dr. Yves Samson:
acquisition of data, drafting/revising the manuscript. Dr. Yannick
Béjot: acquisition of data, drafting/revising the manuscript. Dr. Ayse Altin-
tas: acquisition of data, drafting/revising the manuscript. Dr. Antti J. Metso:
acquisition of data, drafting/revising the manuscript. Dr. Dominique
Hervé: acquisition of data. Dr. Christoph Lichy: acquisition of data.
Dr. Simon Jung: acquisition of data, drafting/revising the manuscript.
Dr. Urs Fischer: acquisition of data. Dr. Chantal Lamy: acquisition of data,
drafting/revising the manuscript. Dr. Armin Grau: acquisition of data,
drafting/revising the manuscript. Dr. Hugues Chabriat: acquisition of
data, drafting/revising the manuscript. Dr. Valeria Caso: acquisition of data,
drafting/revising the manuscript. Dr. Philippe A. Lyrer: acquisition of
data, drafting/revising the manuscript. Dr. Christian Stapf: acquisition of
data. Dr. Turgut Tatlisumak: acquisition of data, drafting/revising the man-
uscript. Dr. Tobias Brandt: acquisition of data, drafting/revising the man-
uscript. Dr. Elisabeth Tournier-Lasserve: drafting/revising the manuscript.
Dr. Dominique P. Germain: acquisition of data, drafting/revising the man-
uscript. Dr. Michael Frank: acquisition of data, drafting/revising the man-
uscript. Dr. Ralf W. Baumgartner: acquisition of data, drafting/revising
the manuscript. Dr. Caspar Grond-Ginsbach: acquisition of data, drafting/
revising the manuscript. Dr. Marie-Germaine Bousser: analysis and interpre-
tation, acquisition of data, drafting/revising the manuscript, obtaining fund-
ing. Dr. Didier Leys: analysis and interpretation, acquisition of data, drafting/
revising the manuscript, obtaining funding. Dr. Jean Dallongeville: analysis
and interpretation, acquisition of data, drafting/revising the manuscript,
obtaining funding. Dr. Anna Bersano: study concept and design, analysis
and interpretation, study supervision or coordination, drafting/revising the
manuscript, obtaining funding, acquisition of data. Dr. Marcel Arnold: study
concept and design, analysis and interpretation, study supervision or coordi-
nation, drafting/revising the manuscript, acquisition of data.
ACKNOWLEDGMENT
The authors thank the staff and participants of all centers from the
CADISP study and the Paris-Lariboisière/Zürich/Bern CeAD registry
for their important contributions: Mrs. Marja Metso (RN), Department
of Neurology, Helsinki University Central Hospital, Helsinki, Finland;
Ms. Laurence Bellengier (MS), Pr. Christian Libersa (MD, PhD),
Pr. Dominique Deplanque (MD, PhD), Centre d’Investigation Clinique,
University Hospital of Lille, France; Dr. Nathalie Fievet (PhD), INSERM
U744, Pasteur Institute, Lille, France; Dr. Jean-Christophe Corvol (MD,
PhD), Mrs. Sylvie Montel (RN), and Mrs. Christine Rémy (RN), Centre
d’Investigation Clinique, Pitié-Salpêtrière University Hospital, Paris,
France; Ana Lopes Da Cruz (PhD), Laboratory of Experimental Neurol-
ogy, ULB, Brussels, Belgium; Annet Tiemessen (MS), Stroke Team, Uni-
versity Hospital Basel, Switzerland; Dr. Raffaele Palmirotta (MD, PhD),
Department of Laboratory Medicine and Advanced Biotechnologies,
IRCCS San Raffaele, Rome, Italy; and Mrs. Marianne Kormann (RN)
and Mrs. Andrea Surtmann Huguenin (RN), Department of Neurology,
University Hospital Inselspital, Bern, Switzerland. The authors also thank
Dr. William R. Davidson, Jr., at Penn State Hershey Heart and Vascular
Institute, PA, for the clinical information he kindly provided.
STUDY FUNDING
Contrat de Projet Etat-Region; Projet Hospitalier de Recherche Clinique
Régional; Fondation de France; Adrinord-EA2691; Institut Pasteur de
Lille; INSERM U744; Emil Aaltonen, Paavo Ilmari Ahvenainen, Päivikki
and Sakari Sohlberg, Aarne Koskelo, Maire Taponen, Aarne and Aili
Turunen, Biomedicum Helsinki Foundation, Finnish Brain Foundation,
Lilly, Alfred Kordelin, Orion-Farmos and Maud Kuistila Foundations;
Finnish Medical Foundation; Helsinki University Central Hospital
Research Fund; Academy of Finland; Helsinki University Medical Foun-
dation; Basel Stroke-Funds; Käthe-Zingg-Schwichtenberg Fonds (Swiss
Academy of Medical Sciences); Swiss Heart Foundation; Swiss National
Science Foundation. Stéphanie Debette is supported by a Chair of
Excellence grant from the French National Research Agency (Agence
Nationale de la Recherche) and from the Leducq Foundation. Vincent
Thijs is supported by a Clinical Investigatorship from FWO Flanders.
DISCLOSURE
The authors report no disclosures relevant to the manuscript. Go to
Neurology.org for full disclosures.
Received March 10, 2014. Accepted in final form August 26, 2014.
REFERENCES
1. Debette S, Markus HS. The genetics of cervical artery dis-
section: a systematic review. Stroke 2009;40:e459–e466.
2. Grond-Ginsbach C, Debette S. The association of connec-
tive tissue disorders with cervical artery dissections. Curr
Mol Med 2009;9:210–214.
3. Schievink WI, Mokri B, Piepgras DG, Kuiper JD. Recur-
rent spontaneous arterial dissections: risk in familial versus
nonfamilial disease. Stroke 1996;27:622–624.
4. Debette S, Germain DP. Neurologic manifestations
of inherited disorders of connective tissue. Handb Clin
Neurol 2014;119:565–576.
5. Debette S, Grond-Ginsbach C, Bodenant M, et al. Dif-
ferential features of carotid and vertebral artery dissections:
the CADISP study. Neurology 2011;77:1174–1181.
6. von Babo M, De Marchis GM, Sarikaya H, et al. Differ-
ences and similarities between spontaneous dissections of
the internal carotid artery and the vertebral artery. Stroke
2013;44:1537–1542.
7. Arnold M, Kappeler L, Georgiadis D, et al. Gender differ-
ences in spontaneous cervical artery dissection. Neurology
2006;67:1050–1052.
8. Debette S, Metso TM, Pezzini A, et al. CADISP-genetics:
an international project searching for genetic risk factors of
cervical artery dissections. Int J Stroke 2009;4:224–230.
9. Debette S, Metso T, Pezzini A, et al. Association of vascular
risk factors with cervical artery dissection and ischemic
stroke in young adults. Circulation 2011;123:1537–1544.
10. De Paepe A, Malfait F. The Ehlers-Danlos syndrome: a
disorder with many faces. Clin Genet 2012;82:1–11.
11. Beighton P, De Paepe A, Steinmann B, Tsipouras P,
Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology,
Villefranche, 1997. Ehlers-Danlos National Foundation
(USA) and Ehlers-Danlos Support Group (UK). Am J
Med Genet 1998;77:31–37.
12. Loeys BL, Dietz HC, Braverman AC, et al. The revised
Ghent nosology for the Marfan syndrome. J Med Genet
2010;47:476–485.
13. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in
osteogenesis imperfecta. J Med Genet 1979;16:101–116.
14. Lee VH, Brown RD Jr, Mandrekar JN, Mokri B. Inci-
dence and outcome of cervical artery dissection: a
population-based study. Neurology 2006;67:1809–1812.
15. Debette S, Leys D. Cervical-artery dissections: predisposing fac-
tors, diagnosis, and outcome. Lancet Neurol 2009;8:668–678.
16. Grond-Ginsbach C, de Freitas GR, Campos CR, et al. Famil-
ial occurrence of cervical artery dissection: coincidence or sign
of familial predisposition? Cerebrovasc Dis 2012;33:466–470.
17. Germain DP. Ehlers-Danlos syndrome type IV. Orphanet
J Rare Dis 2007;2:32.
18. North KN, Whiteman DA, Pepin MG, Byers PH. Cere-
brovascular complications in Ehlers-Danlos syndrome type
IV. Ann Neurol 1995;38:960–964.
19. Pepin M, Schwarze U, Superti-Furga A, Byers PH.
Clinical and genetic features of Ehlers-Danlos syndrome
8 Neurology 83 November 25, 2014
ª 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
type IV, the vascular type. N Engl J Med 2000;342:
673–680.
20. Keane MG, Pyeritz RE. Medical management of Marfan
syndrome. Circulation 2008;117:2802–2813.
21. Pezzini A, Drera B, Del Zotto E, et al. Mutations in
TGFBR2 gene cause spontaneous cervical artery dissec-
tion. J Neurol Neurosurg Psychiatry 2011;82:1372–1374.
22. Loeys BL, Dietz HC. Loeys-Dietz syndrome. In:
Pagon RA, Bird TC, Dolan CR, Stephens K, editors.
GeneReviews [Internet]. Seattle: University of Washington;
2008:1993–2014.
23. Martin JJ, Hausser I, Lyrer P, et al. Familial cervical artery
dissections: clinical, morphologic, and genetic studies.
Stroke 2006;37:2924–2929.
24. Kuivaniemi H, Prockop DJ, Wu Y, et al. Exclusion of
mutations in the gene for type III collagen (COL3A1) as
a common cause of intracranial aneurysms or cervical
artery dissections: results from sequence analysis of the
coding sequences of type III collagen from 55 unrelated
patients. Neurology 1993;43:2652–2658.
25. van den Berg JS, Limburg M, Kappelle LJ, Pals G, Arwert F,
Westerveld A. The role of type III collagen in spontaneous
cervical arterial dissections. Ann Neurol 1998;43:494–498.
26. von Pein F, Valkkila M, Schwarz R, et al. Analysis of the
COL3A1 gene in patients with spontaneous cervical artery
dissections. J Neurol 2002;249:862–866.
27. Ulbricht D, Diederich NJ, Hermanns-Le T, Metz RJ,
Macian F, Pierard GE. Cervical artery dissection: an atyp-
ical presentation with Ehlers-Danlos-like collagen pathol-
ogy? Neurology 2004;63:1708–1710.
28. Uhlig P, Bruckner P, Dittrich R, Ringelstein EB,
Kuhlenbaumer G, Hansen U. Aberrations of dermal con-
nective tissue in patients with cervical artery dissection
(sCAD). J Neurol 2008;255:340–346.
29. Brandt T, Hausser I, Orberk E, et al. Ultrastructural con-
nective tissue abnormalities in patients with spontaneous
cervicocerebral artery dissections. Ann Neurol 1998;44:
281–285.
30. Brandt T, Orberk E, Weber R, et al. Pathogenesis of cer-
vical artery dissections: association with connective tissue
abnormalities. Neurology 2001;57:24–30.
31. Wiest T, Hyrenbach S, Bambul P, et al. Genetic analysis
of familial connective tissue alterations associated with cer-
vical artery dissections suggests locus heterogeneity. Stroke
2006;37:1697–1702.
32. Volker W, Kuhlenbaumer G, Dittrich R, et al. Two sets
of identical twins with cervical artery dissection concor-
dant for temporal artery pathology. Neurology 2008;71:
1035–1037.
33. Fischer U, Ledermann I, Nedeltchev K, et al. Quality of
life in survivors after cervical artery dissection. J Neurol
2009;256:443–449.
Neurology 83 November 25, 2014 9
ª 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
DOI 10.1212/WNL.0000000000001027
 published online October 29, 2014Neurology 
Stéphanie Debette, Barbara Goeggel Simonetti, Sabrina Schilling, et al. 
dissection
Familial occurrence and heritable connective tissue disorders in cervical artery
This information is current as of October 29, 2014
Services
Updated Information &
 00000001027.full.html
http://www.neurology.org/content/early/2014/10/29/WNL.00000
including high resolution figures, can be found at:
Supplementary Material
 00000001027.DC2.html
http://www.neurology.org/content/suppl/2014/10/29/WNL.00000
 00000001027.DC1.html
http://www.neurology.org/content/suppl/2014/10/29/WNL.00000
Supplementary material can be found at: 
Subspecialty Collections
 s
http://www.neurology.org//cgi/collection/stroke_in_young_adult
Stroke in young adults
 iology
http://www.neurology.org//cgi/collection/risk_factors_in_epidem
Risk factors in epidemiology
 on
http://www.neurology.org//cgi/collection/carotid_artery_dissecti
Carotid artery dissection
 http://www.neurology.org//cgi/collection/all_genetics
All Genetics
 ease_stroke
http://www.neurology.org//cgi/collection/all_cerebrovascular_dis
All Cerebrovascular disease/Stroke
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://www.neurology.org/misc/about.xhtml#permissions
or in its entirety can be found online at:
Information about reproducing this article in parts (figures,tables)
  
Reprints
 http://www.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
